Form D · Biotechnology
Aurion Biotech, Inc.
Seattle, WA · CIK 0001924356
Offering snapshot reported Apr 25, 2022 · SEC filing
- Reported sold
- $26.1M Offering amount: $26.1M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 5, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 25, 2022 | Initial | $26,055,618 | No comparison | 2 | SEC filing |
| Apr 21, 2022 | Initial | $55,293,147 | No comparison | 9 | SEC filing |
| Apr 21, 2022 | Initial | $10,997 | No comparison | 32 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-443194
Source: Form D, filed Apr 25, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeannette Bankes | Director |
| Andrew Elbardissi | Director |
| Tom Frinzi | Director |
| Greg Kunst | Director, Executive |
| Arnaud Lacoste | Executive |
| Patrick Lally | Director |
| Christine Mccauley | Director |
| David Rostov | Executive |
| Link William | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
117 E. Louisa Street #561
Seattle, WA, 98102
Seattle, WA, 98102